Anti-anthrax monoclonal antibodies - IQ TherapeuticsAlternative Names: Anthraxumab; anti-LF; anti-PA; IQ-DAA; IQ-NLF; IQ-NPA; IQNLF-1
Latest Information Update: 29 Apr 2011
At a glance
- Originator IQ Therapeutics
- Class Antibacterials; Monoclonal antibodies
- Mechanism of Action Anthrax toxin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Phase I Anthrax